Kailera Therapeutics (NASDAQ:KLRA) Trading Up 7.9% - Here's Why

Key Points

• Kailera Therapeutics shares rose 7.9% to $16.62 in midday trading, although trading volume was down 74% from the stock’s average daily volume.
• Analyst sentiment is generally positive, with the stock receiving a “Moderate Buy” consensus rating and an average price target of $42.75; individual targets range as high as $48.
• The clinical-stage obesity-care biotechnology company reported a quarterly loss of $1.09 per share, missing estimates by $0.35, while major institutional investors—including Atlas Venture and Wellington Management—built substantial positions.

Shares of Kailera Therapeutics, Inc. (NASDAQ:KLRA - Get Free Report) shot up 7.9% during mid-day trading on Tuesday . The company traded as high as $16.69 and last traded at $16.62. Approximately 185,957 shares changed hands during trading, a decline of 74% from the average daily volume of 720,033 shares. The stock had previously closed at $15.40.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on KLRA shares. Leerink Partners began coverage on Kailera Therapeutics in a report on Tuesday, May 12th. They issued an "outperform" rating and a $36.00 price target on the stock. William Blair initiated coverage on Kailera Therapeutics in a report on Tuesday, May 12th. They set an "outperform" rating for the company. Wall Street Zen lowered Kailera Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, May 30th. Jefferies Financial Group began coverage on Kailera Therapeutics in a research note on Tuesday, May 12th. They issued a "buy" rating and a $48.00 target price on the stock. Finally, Evercore assumed coverage on Kailera Therapeutics in a research report on Tuesday, May 12th. They set an "outperform" rating for the company. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $42.75.

Kailera Therapeutics Price Performance

The business's 50 day simple moving average is $18.94. The firm has a market cap of $2.20 billion and a PE ratio of -0.00.

Kailera Therapeutics (NASDAQ:KLRA - Get Free Report) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($1.09) EPS for the quarter, missing analysts' consensus estimates of ($0.74) by ($0.35). As a group, analysts expect that Kailera Therapeutics, Inc. will post -3.89 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. California State Teachers Retirement System bought a new stake in shares of Kailera Therapeutics during the 2nd quarter worth approximately $309,000. Frazier Life Sciences Management L.P. acquired a new stake in shares of Kailera Therapeutics in the 2nd quarter valued at approximately $24,233,000. Wellington Management Group LLP bought a new position in shares of Kailera Therapeutics in the second quarter valued at $64,308,000. Finally, Atlas Venture Life Science Advisors LLC bought a new position in shares of Kailera Therapeutics in the second quarter valued at $113,923,000.

Kailera Therapeutics Company Profile

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source